Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial-Reference-Cited by-同舟云学术

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial

Published:2019-07 Issue:7 Volume:4 Page:501-510
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Yamada Yasuhide,Boku Narikazu,Mizusawa Junki,Iwasa Satoru,Kadowaki Shigenori,Nakayama Norisuke,Azuma Mizutomo,Sakamoto Takeshi,Shitara Kohei,Tamura Takao,Chin Keisho,Hata Hiroaki,Nakamori Mikihito,Hara Hiroki,Yasui Hirofumi,Katayama Hiroshi,Fukuda Haruhiko,Yoshikawa Takaki,Sasako Mitsuru,Terashima Masanori

Funder

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference31 articles.

1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 v 1.0. IARC CancerBase No. 11;Ferlay,2013

2. Impact of endoscopic screening on mortality reduction from gastric cancer;Hamashima;World J Gastroenterol,2015

3. Adjuvant chemotherapy for gastric cancer with S-1 an oral fluoropyrimidine;Sakuramoto;N Engl J Med,2007

4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study;Boku;Lancet Oncol,2009

5. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer;Koizumi;Lancet Oncol,2008

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial;Gastric Cancer;2024-08-20

2. Gastric Cancer Genetics and Its Implications for Diagnosis, Prognosis, and Treatment of the Disease;The Korean Journal of Helicobacter and Upper Gastrointestinal Research;2024-06-10

3. Impact of immune checkpoint inhibitors on survival outcomes in advanced gastric cancer in Japan: A real‐world analysis;Cancer Medicine;2024-06

4. PDLIM1 Inhibits Chemoresistance by Blocking DNA Damage Repair in Gastric Cancer;Recent Patents on Anti-Cancer Drug Discovery;2024-05-22

5. Empagliflozin protective effects against cisplatin-induced acute nephrotoxicity by interfering with oxidative stress and inflammation in Wistar rats;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-04-21